Skip to main content
TipRanks
Go Ultimate75% OFF

TransThera Sciences (Nanjing). Inc. (2617) Stock Price & Analysis

5 Followers

2617 Stock Chart & Stats

HK$7.26-HK$0.32(-4.16%)
At close: 4:00 PM GMT+8
HK$7.5HK$10Aug 24Sep 7Sep 21Oct 5Oct 20Nov 2Nov 16
Day’s Range
HKD 7.22 - HKD 7.80
52-Week Range
HKD 7.22 - HKD 221.40
Previous Close
HKD 7.58
Volume
N/A
Average Volume (3M)
3.18M
Market Cap
HKD 2.27B
Enterprise Value
HKD 3.65B
Total Cash (Recent Filing)
HKD 925.22M
Total Debt (Recent Filing)
HKD 5.61M
Price to Earnings (P/E)
―
Beta
2.68
Next Earnings
N/A
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage

Very low debt relative to equity limits refinancing and interest-rate exposure, giving the company greater financial flexibility while it develops its pipeline. This conservative capital structure is a durable support compared with a heavily leveraged biotechnology business facing extended development timelines.

Proprietary Drug Development Focus

A focus on proprietary small-molecule therapeutics gives TransThera an identifiable research-led business model rather than dependence on mature commercial products. Advancing candidates through discovery, preclinical work, and clinical trials creates potential for longer-term product ownership and commercialization.

Improving Free Cash Flow Trend

Free cash flow improvement in consecutive years indicates some progress in controlling cash consumption, even though the business remains heavily cash negative. If sustained alongside development activity, this trend could extend the company’s funding runway and moderate the pace of balance-sheet erosion.

Bears Say

No Recent Revenue

Zero revenue in the two most recent annual periods shows that the pipeline has not yet translated into commercial sales. This leaves the company without an operating revenue base to absorb research costs, support recurring cash generation, or demonstrate near-term operating leverage.

Persistent Large Losses

Large and persistent net losses indicate that development spending continues to outweigh any operating contribution. The wider loss in 2025 suggests profitability remains distant, limiting internally generated capital and increasing the importance of successful clinical and commercialization progress.

Material Cash Burn

Substantial annual cash consumption reduces financial flexibility even with low leverage, because ongoing research and clinical development must be funded while operating cash inflows remain absent. Persistent burn can pressure equity and assets and may create future external funding needs.

TransThera Sciences (Nanjing). Inc. News

2617 FAQ

What was TransThera Sciences (Nanjing). Inc.’s price range in the past 12 months?
TransThera Sciences (Nanjing). Inc. lowest stock price was HK$7.22 and its highest was HK$221.40 in the past 12 months.
What is TransThera Sciences (Nanjing). Inc.’s market cap?
TransThera Sciences (Nanjing). Inc.’s market cap is HK$2.27B.
When is TransThera Sciences (Nanjing). Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were TransThera Sciences (Nanjing). Inc.’s earnings last quarter?
TransThera Sciences (Nanjing). Inc. released its earnings results on Aug 26, 2026. The company reported -HK$0.267 earnings per share for the quarter.
Is TransThera Sciences (Nanjing). Inc. overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does TransThera Sciences (Nanjing). Inc. pay dividends?
TransThera Sciences (Nanjing). Inc. does not currently pay dividends.
What is TransThera Sciences (Nanjing). Inc.’s EPS estimate?
TransThera Sciences (Nanjing). Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does TransThera Sciences (Nanjing). Inc. have?
TransThera Sciences (Nanjing). Inc. has 313,347,700 shares outstanding.
What happened to TransThera Sciences (Nanjing). Inc.’s price movement after its last earnings report?
TransThera Sciences (Nanjing). Inc. reported an EPS of -HK$0.267 in its last earnings report. Following the earnings report the stock price went up 0.785%.
Which hedge fund is a major shareholder of TransThera Sciences (Nanjing). Inc.?
Currently, no hedge funds are holding shares in HK:2617
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology